Maxim Group Keeps a Buy Rating on BioLife Solutions (BLFS)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a price target of $24. The company’s shares opened today More »

Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Agile Therapeutics (AGRX – Research Report) yesterday and set a price target of $3. The company’s shares opened today at $1.33. McCarthy More »